Venus Remedies bags UK MHRA marketing nod for chemotherapy drug Cisplatin
Advertisement
Chandigarh: Venus Remedies Ltd, a provider of cancer drugs worldwide, has secured marketing authorisation from the UK for Cisplatin, a chemotherapy drug used as a first-line treatment for advanced ovarian cancer, testicular cancer and bladder carcinoma.
"This marketing authorisation granted to Venus Pharma GmbH, the German subsidiary of Venus Remedies, by one of the world's most stringent healthcare regulatory agencies will enable the company to offer its affordable range of cancer drugs to the National Health Service (NHS) in the UK and neighbouring countries," the company stated.
The registration for Cisplatin will also expedite the process of registering the oncology products of Venus Remedies in many other countries around the world which consider the UK as a reference country for fast-tracking registration and open opportunities for supplying unregistered products to several markets globally.
Saransh Chaudhary, President, Global Critical Care. Venus Remedies Ltd, said, "This year, the company intends to increase its sales in the UK to approximately 2 million Euros. We plan to achieve this by focusing on seven molecules which are already registered in the UK and augmenting their sales by 20% on a year-on-year basis, We are also planning to add new molecules in the UK and other European countries, which will help us expand our operations and improve our sales in these markets."
The global market size of Cisplatin was valued at US $394.5 million in 2021 and is expected to grow to US $661.16 million by 2027 at a CAGR of 8.99%. The UK holds at least 5% of the global market share for this drug.
Pertinently, Venus Remedies has received many marketing authorisations from the UK MHRA for a wide range of drugs, including Gemcitabine, Bortezomib, Meropenem, Docetaxel, Carboplatin and Ceftazidime, to name a few.
"Obtaining marketing authorisations for our drugs in the UK will also help us strengthen our position in regulated markets in the Middle East. Latin America and other markets in Europe. Having product registrations from a recognised regulatory agency like the UK MHRA lends us a lot of credibility and enables us to streamline the registration process in other markets," said Chaudhary.
He said the registration for Cisplatin in the UK would potentially help Venus Remedies in expediting the registration of its oncology product Paclitaxel, which is pending with the MHRA.
"We are also about to apply for the marketing authorisation for Bendamustin, a chemotherapy medication used in the treatment of chronic lymphocytic leukaemia, in the UK," he added.
The registration process for each drug is evaluated on a case-by-case basis, which differs from country to country, taking into account factors like safety, efficacy and quality.
Read also: Venus Remedies gets GMP certification from Saudi Arabia for all production facilities in Baddi
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.